BioSpace News Archive

NRx Pharmaceuticals and HOPE Therapeutics aim to provide highest quality product available to those in need and assure ongoing supply Important step toward goal of providing full suite of supply options, to to provide IV Ketamine to patients and clinics across the country, subject to board approval.

Medicilon, a one-stop pharmaceutical preclinical research and development CRO can simultaneously meet Chinese and American drug discovery and development needs promptly and efficiently with fast initiation times.

Vistagen today announced that company management will present and host one-on-one meetings during the Stifel 2024 Virtual CNS Days taking place March 19 to 20, 2024.

DiaCarta, a leading molecular diagnostics company specializing in personalized patient care through liquid biopsy, proudly announced that Florida Health Department selected “using plasma DNA concentration (DiaCarta’s RadTox™ test) for early detection of treatment response and resistance” through the Casey DeSantis Florida Cancer Innovation Fund.

TransCode Therapeutics, Inc. reported positive proof-of-concept laboratory studies in human cells, advancing its strategic partnership with Akribion Genomics.

Alumis Inc. today announced that Company management will host investor meetings at the 2024 Leerink Partners Global Biopharma Conference on March 12, 2024, in Miami, Florida.

Chromocell Therapeutics Corp. today announced Frank Knuettel, CEO, will present and host one-on-one meetings with investors at the Sidoti March Virtual Investor Conference, taking place on March 13-14, 2024.

Astellas Pharma US, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug and pediatric exclusivity to CRESEMBA® (isavuconazonium sulfate) for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients.

Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced two supply contracts that mark its strategic expansion into the East and Southeast Asian region.

Cadrenal Therapeutics, Inc. today provided a corporate update in connection with the filing of its Annual Report on Form 10-K for the year ended December 31, 2023.